Online discussion of drug side effects and discontinuation among breast cancer survivors

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 3, 2013, Pages 256-262

  Mao, Jun J ^a,b   Chung, Annie ^a   Benton, Adrian ^a   Hill, Shawndra ^c   Ungar, Lyle ^d   Leonard, Charles E ^a   Hennessy, Sean ^a   Holmes, John H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adherence; Adverse effects; Aromatase inhibitor; Breast neoplasm; Health communication; Joint pain; Musculoskeletal; Online; Pharmacoepidemiology

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CALCIUM; CHONDROITIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; EXEMESTANE; FISH OIL; GLUCOSAMINE; HERBACEOUS AGENT; LETROZOLE; MAGNESIUM; MINERAL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; VITAMIN D;

ARTHRALGIA; ARTICLE; BACKACHE; BODY WEIGHT; BONE PAIN; BREAST CANCER; CANCER SURVIVOR; CARPAL TUNNEL SYNDROME; CORTICOSTEROID THERAPY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HAIR LOSS; HEADACHE; HOT FLUSH; HUMAN; INSOMNIA; MUSCULOSKELETAL PAIN; MYALGIA; ONLINE ANALYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SELF REPORT; SIDE EFFECT; SWEATING; TENDINITIS; THYROID DISEASE; TREATMENT OUTCOME;

ADAPTATION, PSYCHOLOGICAL; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; DRUG SUBSTITUTION; FEMALE; HEALTH COMMUNICATION; HEALTH INFORMATION SYSTEMS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOT FLASHES; HUMANS; INTERNET; MEDICATION ADHERENCE; OSTEOPOROSIS; QUALITY OF LIFE; SOCIAL MEDIA; SURVIVORS; WEIGHT GAIN;

EID: 84874508541     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3365     Document Type: Article

References (36)

1. Miniwatts Marketing Group. Internet World Stats: Usage and Population Statistics, 2011. http://www.internetworldstats.com/stats.htm.
2. Fox S. The social life of health information. Pew Research Center Report, 2009.
3. Armstrong N, Powell J. Patient perspectives on health advice posted on Internet discussion boards: a qualitative study. Health Expect 2009; 12: 313-320.
4. Globocan: WHO cancer fact sheet. International Agency for Research on Cancer, 2008. http://globocan.iarc.fr/factsheets/cancers/breast.asp.
5. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med 2000; 343: 1086-1094.
6. Mao JJ, Bowman MA, Stricker CT, et al. Delivery of survivorship care by primary care physicians: the perspective of breast cancer patients. J Clin Oncol 2009; 27: 933-938.
7. Rodgers S, Chen Q. Internet community group participation: Psychosocial benefits for women with breast cancer. J Comput-Mediat Comm 2005; 10: 00.
8. Schultz PN, Stava C, Beck ML, et al. Internet message board use by patients with cancer and their families. Clin J Oncol Nurs 2003; 7:663-667.
9. Macias W, Lewis LS, Smith TL. Health-related message boards/chat rooms on the Web: discussion content and implications for pharmaceutical sponsorships. J Health Commun 2005; 10: 209-223.
10. Nagler RH, Gray SW, Romantan A, et al. Differences in information seeking among breast, prostate, and colorectal cancer patients: Results from a population-based survey. Patient Educ Couns 2010; 81S1: S54-S62.
11. Eysenbach G. The impact of the Internet on cancer outcomes. CA Cancer J Clin 2003; 53: 356-371.
12. Civan A, Pratt W. Threading together patient expertise. AMIA Annu Symp Proc 2007; 2007: 140-144.
13. Bartlett YK, Coulson NS. An investigation into the empowerment effects of using online support groups and how this affects health professional/patient communication. Patient Educ Couns 2011; 83: 113-119.
14. Lee CJ, Gray SW, Lewis N. Internet use leads cancer patients to be active health care consumers. Patient Educ Couns 2010; 81(Suppl): S63-S69.
15. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
16. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
17. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
18. Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol 2007; 25: 3797-3799.
19. Mao JJ, Stricker C, Bruner D, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 2009; 115: 3631-3639.
20. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007; 25: 3877-3883.
21. Mao JJ, Su HI, Feng R, et al. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 2011; 13: R8.
22. Morales L, Pans S, Verschueren K, et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008; 26: 3147-3152.
23. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol 2001; 19: 2767.
24. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients. J Clin Oncol 2010; 28: 4120-4128.
25. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2010; 126(2): 529-537.
26. Chlebowski RT. Aromatase inhibitor-associated arthralgias. J Clin Oncol 2009; 27: 4932-4934.
27. Benton A, Ungar L, Hill S, et al. Identifying potential adverse effects using the web: A new approach to medical hypothesis generation. J Biomed Inform 2011; 44(6): 989-996.
28. Benton A, Hill S, Ungar L, et al. A system for de-identifying medical message board text. Ninth International Conference on Machine Learning and Applications: 485-490, 2010.
29. FDA. The Adverse Event Reporting System (AERS): older quarterly data files http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm083765.htm [28 April 2011].
30. Su HI, Sammel MD, Springer E, et al. Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Res Treat 2010; 124(1): 205-211.
31. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med 2010; 362: 865-869.
32. Painter JE, Borba CP, Hynes M, et al. The use of theory in health behavior research from 2000 to 2005: a systematic review. Ann Behav Med 2008; 35: 358-362.
33. Winzelberg AJ, Classen C, Alpers GW, et al. Evaluation of an internet support group for women with primary breast cancer. Cancer 2003; 97: 1164-1173.
34. Barsky AJ, Saintfort R, Rogers MP, et al. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002; 287: 622-627.
35. Medawar C, Herxheimer A, Bell J, et al. Paroxetine, Panorama and user reporting of ADRs: Consumer intelligence matters in clinical practice and post-marketing drug surveillance. Int J Risk Saf Med 2002; 15: 161-169.
36. Greene JA, Kesselheim AS. Pharmaceutical marketing and the new social media. N Engl J Med 2010; 363: 2087-2089.